FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913244551> ?p ?o ?g. }

• W2913244551 endingPage "188" @default.
• W2913244551 startingPage "182" @default.
• W2913244551 abstract "<b><i>Background:</i></b> In Europe IgA nephropathy (IgAN) is detected in 20% of children with glomerular diseases diagnosed by renal biopsy. The outcome during childhood is generally good, but progression in the long-term follow-up may occur in about 20% of children after 20 years. <b><i>Summary:</i></b> In Europe, urine screening programs are not active, and there is variability in the policy to perform renal biopsies in oligo-symptomatic children. Hence, a suitable observational approach to pediatric IgAN is offered by the VALIGA study which included 174 children aged &#x3c; 18 years from 13 European countries followed over a median of 4.4 (2.5–7.5) years. Renal pathology lesions were centrally scored according to the Oxford Classification of IgAN (mesangial hypercellularity, M; endocapillary hypercellularity, E; segmental glomerulosclerosis, S; tubular atrophy/interstitial fibrosis, T; crescents, C [MEST-C]). Children had renal biopsy mostly with normal estimated glomerular filtration rate (eGFR) and moderate proteinuria of a median of 0.84 g/day/1.73 m² (&#x3c; 0.30 g/day/1.73 m² in 30% of the cases). Children showed M1 in 21.8%, E1 in 13.8%, S1 in 42.5%, T1–2 in 6.3%, and C1 in 14.9%. The survival at the combined endpoint of 50% eGFR decrease or end-stage renal disease at 15 years was 94%. The slow progression rate and the limited number of cases progressing to the combined endpoint (6.4%) did not allow the detection of a predictive value of the MEST-C score. Moreover, the predictive value of clinical and pathological features was likely blunted by the use of corticosteroid/immunosuppressive treatment (CS/IS) in 50% of the cases. The survival tree analysis also proved that children &#x3c; 16 years old with IgAN without mesangial hypercellularity (M0) and well preserved eGFR (&#x3e; 90 mL/min/1.73 m²) had a high probability of proteinuria remission during follow-up. Moreover, in this subgroup of children, the benefits of CS/IS therapy reached statistical significance. In Europe, the use of CS/IS treatment in IgAN is still a debated issue, but most children tend to be treated more commonly than adults with CS/IS. A recent uncontrolled study reports a favorable outcome in European children with IgAN and very active acute forms of IgAN with improvement in eGFR and reduction in proteinuria. <b><i>Key Messages:</i></b> In Europe, children with IgAN have a favorable prognosis in the short term, and this may be due also to the frequently adopted CS/IS therapy, particularly with acute and active pathological features. The risk of progression over decades of follow-up remains an unsolved problem which needs to be addressed by controlling subtle chronic pathogenetic factors which work in children as well as in adult cases of IgAN." @default.
• W2913244551 created "2019-02-21" @default.
• W2913244551 creator A5009096793 @default.
• W2913244551 date "2019-01-01" @default.
• W2913244551 modified "2023-10-17" @default.
• W2913244551 title "Pediatric IgA Nephropathy in Europe" @default.
• W2913244551 cites W1980447949 @default.
• W2913244551 cites W2013063926 @default.
• W2913244551 cites W2017031403 @default.
• W2913244551 cites W2056034809 @default.
• W2913244551 cites W2056477902 @default.
• W2913244551 cites W2068209731 @default.
• W2913244551 cites W2072117123 @default.
• W2913244551 cites W2076193619 @default.
• W2913244551 cites W2079362912 @default.
• W2913244551 cites W2093073576 @default.
• W2913244551 cites W2096681927 @default.
• W2913244551 cites W2100730384 @default.
• W2913244551 cites W2108829447 @default.
• W2913244551 cites W2120366573 @default.
• W2913244551 cites W2152853007 @default.
• W2913244551 cites W2161627792 @default.
• W2913244551 cites W2162989837 @default.
• W2913244551 cites W2164177759 @default.
• W2913244551 cites W2167942688 @default.
• W2913244551 cites W2168097071 @default.
• W2913244551 cites W2169111359 @default.
• W2913244551 cites W2181240763 @default.
• W2913244551 cites W2198780076 @default.
• W2913244551 cites W2343467869 @default.
• W2913244551 cites W2410572648 @default.
• W2913244551 cites W2419397876 @default.
• W2913244551 cites W2507566998 @default.
• W2913244551 cites W2515397288 @default.
• W2913244551 cites W2525067757 @default.
• W2913244551 cites W2587118596 @default.
• W2913244551 cites W2794802390 @default.
• W2913244551 cites W2915775190 @default.
• W2913244551 cites W4233557829 @default.
• W2913244551 doi "https://doi.org/10.1159/000495751" @default.
• W2913244551 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6587208" @default.
• W2913244551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31259180" @default.
• W2913244551 hasPublicationYear "2019" @default.
• W2913244551 type Work @default.
• W2913244551 sameAs 2913244551 @default.
• W2913244551 citedByCount "30" @default.
• W2913244551 countsByYear W29132445512020 @default.
• W2913244551 countsByYear W29132445512021 @default.
• W2913244551 countsByYear W29132445512022 @default.
• W2913244551 countsByYear W29132445512023 @default.
• W2913244551 crossrefType "journal-article" @default.
• W2913244551 hasAuthorship W2913244551A5009096793 @default.
• W2913244551 hasBestOaLocation W29132445511 @default.
• W2913244551 hasConcept C126322002 @default.
• W2913244551 hasConcept C126894567 @default.
• W2913244551 hasConcept C134018914 @default.
• W2913244551 hasConcept C142724271 @default.
• W2913244551 hasConcept C159641895 @default.
• W2913244551 hasConcept C2775934546 @default.
• W2913244551 hasConcept C2778415529 @default.
• W2913244551 hasConcept C2778653478 @default.
• W2913244551 hasConcept C2779561371 @default.
• W2913244551 hasConcept C2780091579 @default.
• W2913244551 hasConcept C2780306776 @default.
• W2913244551 hasConcept C2781087799 @default.
• W2913244551 hasConcept C2781184683 @default.
• W2913244551 hasConcept C555293320 @default.
• W2913244551 hasConcept C71924100 @default.
• W2913244551 hasConcept C90924648 @default.
• W2913244551 hasConceptScore W2913244551C126322002 @default.
• W2913244551 hasConceptScore W2913244551C126894567 @default.
• W2913244551 hasConceptScore W2913244551C134018914 @default.
• W2913244551 hasConceptScore W2913244551C142724271 @default.
• W2913244551 hasConceptScore W2913244551C159641895 @default.
• W2913244551 hasConceptScore W2913244551C2775934546 @default.
• W2913244551 hasConceptScore W2913244551C2778415529 @default.
• W2913244551 hasConceptScore W2913244551C2778653478 @default.
• W2913244551 hasConceptScore W2913244551C2779561371 @default.
• W2913244551 hasConceptScore W2913244551C2780091579 @default.
• W2913244551 hasConceptScore W2913244551C2780306776 @default.
• W2913244551 hasConceptScore W2913244551C2781087799 @default.
• W2913244551 hasConceptScore W2913244551C2781184683 @default.
• W2913244551 hasConceptScore W2913244551C555293320 @default.
• W2913244551 hasConceptScore W2913244551C71924100 @default.
• W2913244551 hasConceptScore W2913244551C90924648 @default.
• W2913244551 hasIssue "3" @default.
• W2913244551 hasLocation W29132445511 @default.
• W2913244551 hasLocation W29132445512 @default.
• W2913244551 hasLocation W29132445513 @default.
• W2913244551 hasLocation W29132445514 @default.
• W2913244551 hasOpenAccess W2913244551 @default.
• W2913244551 hasPrimaryLocation W29132445511 @default.
• W2913244551 hasRelatedWork W1976143010 @default.
• W2913244551 hasRelatedWork W2013701055 @default.
• W2913244551 hasRelatedWork W2057561566 @default.
• W2913244551 hasRelatedWork W2071521492 @default.
• W2913244551 hasRelatedWork W2126629494 @default.
• W2913244551 hasRelatedWork W2402220221 @default.

• next